- 27 Downloads
Granisetron (BRL 43694) is a highly selective 5-HT3 receptor antagonist which possesses significant antiemetic activity, likely mediated through antagonism of 5-HT3 receptors on abdominal vagal afferents and possibly in or near the chemoreceptor trigger zone. Clinical trials in cancer patients demonstrate that, compared with placebo, granisetron significantly reduces the incidence of nausea and vomiting for 24 hours after administration of high-dose cisplatin. In large comparative trials, 70% of patients who received granisetron prior to cisplatin or other chemotherapy experienced complete inhibition of vomiting with little or no nausea for 24 hours after antineoplastic administration; these results were similar to those obtained with high-dose metoclopramide plus dexamethasone, and superior to a combination of chlorpromazine plus dexamethasone, or prochlorperazine plus dexamethasone, or methylprednisolone monotherapy. The most frequently reported adverse event associated with granisetron administration is headache which occurs in about 10 to 15% of patients while constipation, somnolence, diarrhoea and minor transient changes in blood pressure have been reported less frequently. Extrapyramidal effects, which can occur with high-dose metoclopramide and may be a limiting factor in its use, have not been noted with granisetron administration.
Thus, granisetron is an effective, well tolerated and easily administered agent for the prophylaxis of nausea and vomiting induced by cancer chemotherapy which appears to be devoid of extrapyramidal side effects associated with metoclopramide. As a member of a new class of drugs, the selective 5-HT3 receptor antagonists, granisetron provides the medical oncologist with a new, potentially more acceptable antiemetic therapy.
Granisetron is a potent and selective antagonist of 5-HT3 receptors in the peripheral as well as central nervous system. It inhibits various effects on isolated animal tissues induced by serotonin including contractions of guinea-pig ileum and tachycardia of rabbit heart. In addition, granisetron blocks the depolarising effects of serotonin in the rabbit vagus nerve which are mediated by 5-HT3 receptors. Binding studies show no significant interaction with other receptors. 5-HT3 receptors have also been identified in the area postrema (the chemoreceptor trigger zone for emesis), the nucleus tractus solitarius and in greater concentrations in the brain stem, the main terminus for vagal afferent fibres. Granisetron has 4000 to 40 000 times greater affinity for5-HT3 receptors in rat and guinea-pig brain than for other receptors studied including 5-HT1, 5-HT2, dopamine D2, histamine H1, benzodiazepine and opioid receptors.
Antiemetic studies in the ferret showed that parenteral or oral administration of granisetron reduced the incidence of, or completely prevented, emesis induced by radiation or cytotoxic drugs, including cisplatin. In humans and animals already experiencing cytotoxic-induced vomiting, granisetron completely and rapidly abolished emesis. In the ferret, emesis stopped within 15 to 60 seconds of parenteral granisetron administration. These cytotoxic stimuli cause cellular damage, which may precipitate the release of serotonin from enterochromaffin cells of the intestinal mucosa, activating vagal and possibly splanchnic afferent neurons, which elicit the vomiting response. Granisetron probably prevents nausea and vomiting evoked by antineoplastic drugs and radiation by antagonising the effects of serotonin at 5-HT3 receptors on the abdominal afferents supplying the upper small intestine and possibly in the nucleus tractus solitarius or the area postrema.
After rapid intravenous administration of granisetron 20 or 40 μg/kg to healthy volunteers, mean peak plasma concentrations were 13.7 and 42.8 μg/L, respectively. Peak plasma concentrations and area under the plasma concentration-time curve (AUC) increase roughly in proportion to dose, while half-life, volume of distribution and clearance values remain essentially unchanged, indicating linear kinetics over a wide range of dosages (10 to 300 μg/kg). The volume of distribution of granisetron is 2.2 to 3.3 L/kg in cancer patients. Mean plasma half-life is longer in cancer patients (about 10 to 12 hours) than in healthy volunteers (3.1 to 5.9 hours). Furthermore, total body clearance values are lower and AUC values are higher in cancer patients, and together, these findings may reflect differences in drug elimination due to underlying disease processes, increased age of cancer patients relative to healthy volunteers or other factors. Elimination of granisetron is primarily by non-renal mechanisms, with only 8 to 15% of the parent compound recovered in the urine.
Most clinical trials involved the intravenous administration of granisetron to cancer patients, 5 minutes prior to a variety of chemotherapeutic regimens, and have evaluated its antiemetic efficacy over the following 24-hour period, continuing with evaluation during the next 6 days. Dose-finding studies showed no significant difference in the antiemetic response of cancer patients receiving chemotherapy to single intravenous doses of granisetron 40 μg/kg and 160 μg/kg (with 1 or 2 supplemental doses of 40 μg/kg allowed for breakthrough symptoms). Emesis was completely inhibited, with no or only mild nausea in 57 to 81% of patients in these studies. Granisetron was significantly superior to placebo in preventing emesis evoked by cisplatin, and was very effective as an intervention agent, quickly abolishing emesis in most patients unresponsive to placebo. Granisetron was at least as effective over the initial 24 hours following chemotherapy as a combination of high-dose metoclopramide plus dexamethasone with or without diphenhydramine, and was superior to chlorpromazine plus dexamethasone, or prochlorperazine plus dexamethasone, or methylprednisolone monotherapy. In the larger comparative studies, granisetron completely prevented emesis in 70% of cancer patients for the 24 hours after receiving chemotherapy. The antiemetic efficacy of granisetron over 7 days following chemotherapy is equivalent to combinations of high-dose metoclopramide plus dexamethasone, or chlorpromazine plus dexamethasone, or alizapride plus dexamethasone. In a noncomparative trial, 56% of patients receiving granisetron did not experience emesis or nausea during the initial 24 hours following total body irradiation, and only 19% of patients reported emesis over the next 6 days.
Granisetron was generally well tolerated in clinical trials. The most frequent adverse event observed with granisetron administration was headache, which occurred in about 10 to 15% of patients. Other less frequently reported adverse events included constipation, somnolence and diarrhoea. Transient changes in blood pressure were also observed which resolved without treatment in all cases and were generally considered to be clinically insignificant. Extrapyramidal effects, which occur in up to 5% of patients receiving high-dose metoclopramide, were not experienced with granisetron administration in any study.
Dosage and Administration
Little or no difference in antiemetic efficacy and tolerability was observed in clinical trials comparing low doses (40 μg/kg) with high doses (160 μg/kg). In most studies, single intravenous doses of 40 to 160 μg/kg were administered 5 minutes before chemotherapy, and up to 2 supplemental doses of 40 μg/kg were permitted during the initial 24 hours for breakthrough symptoms. Granisetron was usually diluted in normal saline and administered intravenously over 2 to 30 minutes. The manufacturer has simplified the dosage regimen to a standard fixed 3mg intravenous dose infused over 5 minutes.
KeywordsOndansetron Granisetron Nucleus Tractus Solitarius Area Postrema Antiemetic Efficacy
Unable to display preview. Download preview PDF.
- Allen A, Asgill CC, Pierce DM, Upward JW, Zussman BD. Pharmacokinetics of ascending intravenous doses of granisetron, a novel 5-HT3-receptor antagonist. British Journal of Clinical Pharmacology 29: 619P–620P, 1990Google Scholar
- Ashby Jr CR, Edwards E, Harkins KL, Wang RY. Differential effect of typical and atypical antipsychotic drugs on the suppressant action of 2-methylserotonin on medial prefrontal cortical cells: a microiontophoretic study. European Journal of Pharmacology 166: 583–584, 1989PubMedCrossRefGoogle Scholar
- Barnes JM, Barnes NM, Cooper S. Behavioural pharmacology of 5-HT3receptor ligands. Neuroscience and Biobehavioral Reviews, In press, 1991Google Scholar
- Boyle EA, Miner WD, Sanger GJ. Anti-emetic activity of BRL 43694, a novel 5HT3-receptor antagonist. British Journal of Cancer 56(2): 227, 1987aGoogle Scholar
- Boyle EA, Miner WD, Sanger GJ. Different anti-cancer therapies evoke emesis by mechanisms that can be blocked by the 5-HT3receptor antagonist BRL 43694. British Journal of Pharmacology 91 (Suppl.): 418P, 1987bGoogle Scholar
- Bremer K, Smit P, on behalf of the Granisetron Study Group. Granisetron compared to a combination of abizapride plus dexamethasone for the prophylaxis and control of cytotoxic induced emesis over 5 days. Annals of Oncology 1 (Suppl.): 109, 1990Google Scholar
- Clarkson A, Coates PE, Zussman BD. A specific h.p.l.c. method for the determination of BRL 43694 in plasma and urine. British Journal of Clinical Pharmacology 25(1): 136P, 1988Google Scholar
- Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic antiemetic and intervention agent in high-dose cisplatin-induced emesis. European Journal of Cancer 26 (Suppl. 1): 23–27, 1990Google Scholar
- Elliott P, Seemungal BM, Wallis DI. Antagonism of the effects of 5-hydroxytryptamine on the rabbit isolated vagus nerve by BRL 43694 and metoclopramide. Naunyn-Schmiedebergs Archives of Pharmacology 341: 503–509, 1990Google Scholar
- Fake CS, King FD, Sanger GJ. BRL 43694: a potent and novel 5-HT3 receptor antagonist. British Journal of Pharmacology 91: 335P, 1987Google Scholar
- Furue H, Oota K, Taguchi T, Niitani H, Ogawa N. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs. II. Multicentred, placebo-controlled, double-blind comparative study. Rinsho Iyaku 6(Suppl. 5): 63–86, 1990Google Scholar
- Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New England Journal of Medicine 305: 905–909, 1981PubMedCrossRefGoogle Scholar
- Jones B. 5-HT3Receptor antagonists in anxiety and schizophrenia. Drug News and Perspectives 3(2): 106–111, 1990Google Scholar
- King FD, Sanger GJ. 5-HT3Receptor antagonists. Drugs of the Future 14(9): 875–889, 1989Google Scholar
- Koyanagi J, Kumakura H, Nishioka Y, Sato M, Nakajima T, et al. A phase I study of granisetron (third report) - safety and pharmacokinetics of granisetron following 2-minute single intravenous injection in Japanese healthy volunteers. Rinsho Iyaku 6 (Suppl. 5): 35–47, 1990Google Scholar
- Kris MG, Leslie B, Tyson LB, Gralla RJ, Clark RA, et al. Extrapyramidal reactions with high-dose metoclopramide. Correspondence. New England Journal of Medicine 309(7): 433, 1983Google Scholar
- Kumakura H, Koyanagi J, Nishioka Y, Sato M, Nakajima T, et al. Phase I study of granisetron (second report) - pharmacokinetics of granisetron following single and repeat intravenous drip infusion in Japanese healthy volunteers. Rinsho Iyaku 6 (Suppl. 5): 25–34, 1990Google Scholar
- Lemerle J, Lartigan E, Godzinski J, McDowel H, Upward J, et al. Efficacy and safety of granisetron in the prevention of chemotherapy induced emesis in children. Abstract. Medical and Pediatric Oncology 19: 420, 1991Google Scholar
- Leonhardt S, Herrick-Davis K, Titeler M. Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein/Journal of Neurochemistry 53: 465–471, 1989Google Scholar
- Machida T, Masuda F, Onodera S, Kodera S. Clinical evaluation of granisetron against nausea and vomiting induced by anti-cancer drugs IV - study on usefulness of metoclopramide and granisetron. Rinsho Iyaku 6 (Suppl. 5): 107–120, 1990Google Scholar
- Marty M, on behalf of the Granisetron Study Group. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. European Journal of Cancer 26 (Suppl. 1): 28–32, 1990Google Scholar
- Monkovic I. New benzamide anti-emetics. Drugs of the Future 14(1): 41–49, 1989Google Scholar
- Montgomery SA, Fineberg N. Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illnesses? British Journal of Psychiatry 155(Suppl. 8): 63–70, 1989Google Scholar
- Niitani H, Hasegawa K, Kuriyama T, Nagao K, Yamaguchi T. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs. III. Comparative crossover study with methylprednisolone. Rinsho Iyaku 6 (Suppl. 5): 87–105, 1990Google Scholar
- Prentice H, Granisetron Satellite Symposium, UICC Congress, Hamburg, Germany, August 17, 1990Google Scholar
- Priestman TJ. Clinical studies with ondansetron in the control of radiation-induced emesis. European Journal of Clinical Oncology 25 (Suppl. 1): S29–S33, 1989Google Scholar
- Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR. Influence of age and gender on the pharmacokinetics of ondansetron, a 5-HT3antagonist. Abstract PII-52. Clinical Pharmacology and Therapeutics 47: 161, 1990Google Scholar
- Smith IE, on behalf of the Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving moderately cytostatic chemotherapy. European Journal of Cancer 26 (Supp. 1): 19–23, 1990Google Scholar
- Soukop M, on behalf of the Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. European Journal of Cancer 26 (Suppl. 1): 15–19, 1990Google Scholar
- Venner P, for the Clinical Trials Group of the National Cancer Institute of Canada. Granisetron for high dose cisplatin (HDCP) induced emesis: a randomized double-blind study. Abstract 1238. Proceedings of the American Society of Clinical Oncology 9: 320, 1990Google Scholar
- Warr D. A double-blind randomized comparison of the novel antiemetic BRL 43694A versus dexamethasone plus prochlorperazine. Abstract P-0515. Proceedings of the European Congress of Clinical Oncology 5: 1989Google Scholar
- Zussman BD, Clarkson A, Coates PE, Rapeport WG. The pharmacokinetic profile of BRL 43694, a novel 5-HT3receptor antagonist, in healthy male volunteers. British Journal of Clinical Pharmacology 25(1): 107P–108P, 1988Google Scholar